<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  
  
  
  
  
  
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clinics (Sao Paulo)</journal-id>
      <journal-title-group>
        <journal-title>Clinics (Sao Paulo, Brazil)</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1807-5932</issn>
      <issn pub-type="epub">1980-5322</issn>
      <publisher>
        <publisher-name>Hospital das Cl&#xED;nicas da Faculdade de Medicina da Universidade
          de S&#xE3;o Paulo    </publisher-name>
      </publisher>
    </journal-meta>
    <article-meta><article-id pub-id-type="pmid">19142556</article-id><article-id pub-id-type="pmc">2671966</article-id><?properties open_access?>
      <article-id pub-id-type="doi">10.1590/S1807-59322009000100014</article-id>
      <article-id pub-id-type="publisher-id">cln64_1p0071</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Severe and Prolonged Cholestasis Caused by Trimethoprim-Sulfamethoxazole: A
          Case Report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Faria</surname>
            <given-names>Luciana C.</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn1-14-le-0032">I</xref>
          <xref ref-type="corresp" rid="c1-14-le-0032"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Resende</surname>
            <given-names>Clarissa C.</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn1-14-le-0032">I</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Couto</surname>
            <given-names>Cl&#xE1;udia A.</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn1-14-le-0032">I</xref>
          <xref ref-type="author-notes" rid="fn2-14-le-0032">II</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Couto</surname>
            <given-names>Osvaldo F.M.</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn1-14-le-0032">I</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fonseca</surname>
            <given-names>L&#xFA;cia P.C.</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn3-14-le-0032">III</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ferrari</surname>
            <given-names>Teresa Cristina A.</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn1-14-le-0032">I</xref>
          <xref ref-type="author-notes" rid="fn3-14-le-0032">II</xref>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn id="fn1-14-le-0032">
          <label>
            <sup>I</sup>
          </label>
          <p>Alfa Institute of Gastroenterology, University Hospital, Federal University of Minas
            Gerais - Belo Horizonte/MG, Brazil</p>
        </fn>
        <fn id="fn2-14-le-0032">
          <label>
            <sup>II</sup>
          </label>
          <p>School of Medicine, Department of Internal Medicine - Belo Horizonte/ MG, Brazil</p>
        </fn>
        <fn id="fn3-14-le-0032">
          <label>
            <sup>III</sup>
          </label>
          <p>Department of Pathology and Legal Medicine, School of Medicine, Federal University of
            Minas Gerais - Belo Horizonte/MG, Brazil</p>
        </fn>
        <corresp id="c1-14-le-0032">Email: <email>lucostafaria@hotmail.com</email>, Tel.: 55 31
          3409.9247 / 3409.9253</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2009</year>
      </pub-date>
      <volume>64</volume>
      <issue>1</issue>
      <fpage>71</fpage>
      <lpage>74</lpage>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2009 Hospital das Cl&#xED;nicas da
        FMUSP</copyright-statement>
      </permissions>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Trimethoprim-sulfamethoxazole (TMP-SMX) is a widely used antibiotic in the prophylaxis and
        treatment of a variety of common infections. Hepatic injuries caused by TMP-SMX are
        considered rare and are classified as unpredictable or idiosyncratic types of hepatotoxic
          reactions.<xref ref-type="bibr" rid="b1-14-le-0032">1</xref> The pattern of injury may be
        characterized by hepatocellular necrosis,<xref ref-type="bibr" rid="b1-14-le-0032">1</xref>,<xref ref-type="bibr" rid="b2-14-le-0032">2</xref> mixed
          hepatocellular-cholestasis,<xref ref-type="bibr" rid="b1-14-le-0032">1</xref>,<xref ref-type="bibr" rid="b3-14-le-0032">3</xref>,<xref ref-type="bibr" rid="b4-14-le-0032">4</xref> or cholestasis.<xref ref-type="bibr" rid="b5-14-le-0032">5</xref>&#x2013;<xref ref-type="bibr" rid="b7-14-le-0032">7</xref> We describe a
        case of severe and prolonged cholestasis, which arose 30 days after a 5-day course of
        TMP-SMX treatment, and provide a review of related cases.</p>
    </sec>
    <sec>
      <title>CASE DESCRIPTION</title>
      <p>A 33-year-old woman with a past history of recurrent urinary tract infection was treated
        with TMP-SMX for 5 days. One month later, she developed malaise, fatigue, anorexia, nausea,
        vomiting, fever, jaundice, dark urine, and a diffuse pruriginous rash. She had been
        previously exposed to this agent in the past. She denied alcohol consumption and any
        previous comorbid condition, and she had not taken any other medication during the last 3
        months. The patient was previously hospitalized in 2 other institutions. Laboratory tests
        performed during the second admission revealed a total bilirubin level of 26.8 mg/dL (upper
        normal limit [UNL] 1.2 mg/dL), conjugated bilirubin of 19.6 mg/ dL (UNL 0.3 mg/dL),
        aspartate aminotransferase (AST) of 154 IU/L (UNL 46 IU/L), alanine aminotransferase (ALT)
        of 63 IU/L (UNL 66 IU/L), alkaline phosphatase of 226 IU/L (UNL 126 IU/L), and albumin of
        2.3 g/dL. Abdominal ultrasound and computed tomography were normal. Tests for antinuclear
        antibody, antibodies against hepatitis C virus, and human immunodeficiency virus (HIV),
        total anti-HBc, and hepatitis B surface antigen were all negative. Liver biopsy demonstrated
        severe cholestasis, with bile inside the hepatocytes and numerous bile casts in the
        canaliculi, predominantly in the pericentrilobular zone. Small numbers of mononuclear cells
        and neutrophils infiltrated into the vicinity of the cholestasis without any other
        inflammatory activity (portal or periportal) or fibrosis. The liver architecture was intact
          (<xref ref-type="fig" rid="f1-14-le-0032">Figure 1</xref>). As the jaundice persisted, the
        patient developed pruritus and lost 15 Kg over 2 months. The patient was then referred to
        our institution for continued investigation. At that time, the total bilirubin was 14.2
        mg/dL, with a conjugated bilirubin level of 13.3 mg/ dL, alkaline phosphatase of 1,273 IU/L,
        gamma glutamyl transpeptidase (GGT) of 877 IU/L (UNL 43 IU/L), AST of 147 IU/L, ALT of 103
        IU/L, International Normalized Ratio (INR) of 1.4, albumin of 2.6 g/dL, and globulins of 3.4
        g/ dL. The patient exhibited normocytic and normochromic anemia (hemoglobin 10.8 g/dL), with
        normal white blood cell (without eosinophilia) and platelet counts. Plasma levels of
        amylase, lipase, urea, creatinin, and glucose were normal. Serologies for hepatitis A, B,
        and C and anti-HIV were negative, as were the autoantibodies (antimitochondrial, anti-smooth
        muscle, anti-liver kidney muscle [LKM]-1, antinucleus, antithyroid peroxidase, and
        antithyroglobulin). Caeruloplasmin, ferritin, alpha-1-antitrypsin, TSH, free thyroxine
        (fT4), IgG, IgM, IgA and alpha-fetoprotein levels were all normal. Upper digestive endoscopy
        and endoscopic retrograde cholangiopancreatography (ERCP) demonstrated no abnormalities.
        Abdominal ultrasound revealed non-specific splenomegaly. Liver biopsy was repeated with
        equivalent results. The pruritus was unresponsive to cholestyramine associated with
        dexclorfeniramine, but it was successfully treated with cholestyramine and hydroxyzine. The
        patient presented with slow and progressive improvement of all clinical and laboratory
        parameters, with complete normalization of the bilirubin levels in 8 months, alkaline
        phosphatase in 16 months, and GGT in 35 months (<xref ref-type="fig" rid="f2-14-le-0032">Figure 2</xref>). She regained weight and is currently asymptomatic and doing well. The
        patient also exhibited normal liver function during a follow-up period of 5 years after
        symptom onset.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>We report a case of severe cholestasis accompanied by important systemic repercussion, as
        evidenced by weight loss (15 Kg in 2 months), hypoalbuminemia, anemia, and a protracted
        course of disease. The exhaustive investigation of other etiologies of liver damage strongly
        suggested a causal association between TMP-SMX and the hepatic lesion in this case. Liver
        biopsy demonstrated cholestasis with minimal lobular inflammatory activity and necrosis.</p>
      <p>Drug-induced liver injury due to TMP-SMX is rare and is classified as either an
        unpredictable or idiosyncratic type of hepatotoxic reaction. The pattern of injury may be
        characterized by hepatocellular necrosis,<xref ref-type="bibr" rid="b1-14-le-0032">1</xref>,<xref ref-type="bibr" rid="b2-14-le-0032">2</xref> mixed
          hepatocellular-cholestasis,<xref ref-type="bibr" rid="b1-14-le-0032">1</xref>,<xref ref-type="bibr" rid="b3-14-le-0032">3</xref>,<xref ref-type="bibr" rid="b4-14-le-0032">4</xref> or cholestasis.<xref ref-type="bibr" rid="b5-14-le-0032">5</xref>&#x2013;<xref ref-type="bibr" rid="b7-14-le-0032">7</xref> The majority of
        the reported cases of TMP-SMX-induced cholestasis were reviewed and are summarized in <xref ref-type="table" rid="t1-14-le-0032">Table 1</xref>.</p>
      <p>In previous reports, TMP-SMX-induced intrahepatic cholestasis was associated with minimal
        hepatocellular inflammation or necrosis, symptom onset of between a few days and a month
        after the beginning of therapy, and a clinical course that usually subsides within a few
          months.<xref ref-type="bibr" rid="b5-14-le-0032">5</xref>,<xref ref-type="bibr" rid="b8-14-le-0032">8</xref>&#x2013;<xref ref-type="bibr" rid="b11-14-le-0032">11</xref> The etiologic role of TMP-SMX has been confirmed in a few cases by either
        inadvertent or deliberate rechallenge.<xref ref-type="bibr" rid="b3-14-le-0032">3</xref>,<xref ref-type="bibr" rid="b8-14-le-0032">8</xref>,<xref ref-type="bibr" rid="b10-14-le-0032">10</xref> In the present case, rechallenge was not accomplished
        because of the clinical severity and prolonged course of the disease. The time interval
        between drug discontinuation and initiation of symptoms in the present case was quite long
        (30 days). However, we could not rule out the possibility of the presence of mild symptoms
        before they became severe enough to be noticed by the patient. Furthermore, the latency
        period between initial ingestion of the drug and hepatic manifestations could range from 5
        to 90 days.<xref ref-type="bibr" rid="b12-14-le-0032">12</xref></p>
      <p>A few reports of prolonged cholestasis induced by TMP-SMX have already been published.<xref ref-type="bibr" rid="b6-14-le-0032">6</xref>,<xref ref-type="bibr" rid="b7-14-le-0032">7</xref>,<xref ref-type="bibr" rid="b13-14-le-0032">13</xref> Mu&#xF1;oz et al.
        described a case of intrahepatic cholestasis associated with prominent hepatocyte lysosomal
        inclusions suggestive of phospholipidosis by electron microscopy, and of severe pruritus
        that lasted 8 months. The symptoms eventually led to the initiation of plasmapheresis.<xref ref-type="bibr" rid="b7-14-le-0032">7</xref> Kowdley et al. reported two cases of severe,
        prolonged cholestasis in which bilirubin normalized within 11&#x2013;12 months and mild
        alkaline phosphatase and GGT level abnormalities lasted for approximately 2 years.<xref ref-type="bibr" rid="b6-14-le-0032">6</xref></p>
      <p>Two cases of TMP-SMX-induced cholestatic liver damage with ductopenia (vanishing bile duct
        syndrome) have also been reported.<xref ref-type="bibr" rid="b14-14-le-0032">14</xref>,<xref ref-type="bibr" rid="b15-14-le-0032">15</xref> Yao et al. reported one such case in which
        jaundice appeared after a 5-day course of therapy and progression to liver failure led to
        liver transplantation 9 months after the onset of the symptoms.<xref ref-type="bibr" rid="b14-14-le-0032">14</xref> The possibility of such clinical evolution should alert
        physicians to the potentially serious cholestatic-pattern of hepatotoxicity associated with
        this commonly used drug.</p>
      <p>The present report and other similar cases demonstrate that cholestasis can be the most
        prominent feature of TMP-SMX-induced liver damage. The high frequency of TMP-SMX
        prescription contrasts with the rarity of well-documented examples of drug-related
        cholestasis or hepatic damage due to the use of TMP-SMX. Nevertheless, the present case and
        other previous cases emphasize the importance of considering drug-induced liver disease
        during differential diagnosis of patients receiving this drug. This is particularly critical
        since TMP-SMX administration must be stopped immediately in order to improve the outcome
        despite the rare need for patients to require liver transplantation as a consequence of
        dug-induced hepatotoxic injury.<xref ref-type="bibr" rid="b15-14-le-0032">15</xref></p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="b1-14-le-0032">
        <label>1.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berg</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Daniel</surname>
              <given-names>PT</given-names>
            </name>
          </person-group>
          <article-title>Co-trimoxazole-induced hepatic injury &#x2013; an analysis of cases
            with hypersensitivity-like reactions</article-title>
          <source>Infection</source>
          <year>1987</year>
          <volume>15</volume>
          <issue>Suppl 5</issue>
          <fpage>S259</fpage>
          <lpage>S264</lpage>
          <pub-id pub-id-type="pmid">3501774</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b2-14-le-0032">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zaman</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Abreo</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Latif</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zibari</surname>
              <given-names>GB</given-names>
            </name>
          </person-group>
          <article-title>Successful orthotopic liver transplantation after
            trimethoprim-sulfamethoxazole associated fulminant liver failure</article-title>
          <source>Clin Transplant</source>
          <year>2003</year>
          <volume>17</volume>
          <fpage>461</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">14703931</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b3-14-le-0032">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thies</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Dull</surname>
              <given-names>WL</given-names>
            </name>
          </person-group>
          <article-title>Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis: inadvertent
            rechallenge</article-title>
          <source>Arch Intern Med</source>
          <year>1984</year>
          <volume>144</volume>
          <fpage>1691</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="pmid">6331808</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b4-14-le-0032">
        <label>4.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kouklakis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mpoumponaris</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zezos</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Moschos</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Koulaouzidis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nakos</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cholestatic hepatitis with severe systemic reactions induced by
            trimethoprim-sulfamethoxazole</article-title>
          <source>Ann Hepatol</source>
          <year>2007</year>
          <volume>6</volume>
          <fpage>63</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">17297432</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b5-14-le-0032">
        <label>5.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abi-Mansur</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ardiaca</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Allam</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shamma&#x2019;A</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Trimethoprim-sulfamethoxazole-induced cholestasis</article-title>
          <source>Am J Gastroenterol</source>
          <year>1981</year>
          <volume>76</volume>
          <fpage>356</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">7325149</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b6-14-le-0032">
        <label>6.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kowdley</surname>
              <given-names>KV</given-names>
            </name>
            <name>
              <surname>Keeffe</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Fawaz</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>Prolonged cholestasis due to trimethoprim sulfamethoxazole</article-title>
          <source>Gastroenterology</source>
          <year>1992</year>
          <volume>102</volume>
          <fpage>2148</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">1587437</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b7-14-le-0032">
        <label>7.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mu&#xF1;oz</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Martinez-Hernandez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Maddrey</surname>
              <given-names>WC</given-names>
            </name>
          </person-group>
          <article-title>Intrahepatic cholestasis and phospholipidosis associated with the use of
            trimethoprim-sulfamethoxazole</article-title>
          <source>Hepatology</source>
          <year>1990</year>
          <volume>12</volume>
          <fpage>342</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">2167870</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b8-14-le-0032">
        <label>8.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ogilvie</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Toghill</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Cholestatic jaundice due to co-trimoxazole</article-title>
          <source>Postgrad Med J</source>
          <year>1980</year>
          <volume>56</volume>
          <fpage>202</fpage>
          <lpage>04</lpage>
          <pub-id pub-id-type="pmid">7393813</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b9-14-le-0032">
        <label>9.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nair</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Geraci</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Trimethoprim-sulfamethoxazole-induced intrahepatic cholestasis</article-title>
          <source>Ann Intern Med</source>
          <year>1980</year>
          <volume>92</volume>
          <fpage>511</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="pmid">7362156</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b10-14-le-0032">
        <label>10.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Steinbrecher</surname>
              <given-names>UP</given-names>
            </name>
            <name>
              <surname>Mishkin</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Sulfamethoxazole-induced hepatic injury</article-title>
          <source>Dig Dis Sci</source>
          <year>1981</year>
          <volume>26</volume>
          <fpage>756</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">7261840</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b11-14-le-0032">
        <label>11.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mcgowan</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Pierce</surname>
              <given-names>EH</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Intrahepatic cholestasis due to trimethoprim-sulfamethoxazole</article-title>
          <source>South Med J</source>
          <year>1981</year>
          <volume>74</volume>
          <fpage>897</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">7256343</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b12-14-le-0032">
        <label>12.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>WM</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced hepatotoxicity</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>349</volume>
          <fpage>474</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">12890847</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b13-14-le-0032">
        <label>13.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruiz-Irastorza</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Montejo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ituarte</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Aguirre</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Colestasis prolongada tras dosis &#xFA;nica de cotrimoxazol</article-title>
          <source>Rev Clin Esp</source>
          <year>1996</year>
          <volume>196</volume>
          <fpage>87</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">8685494</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b14-14-le-0032">
        <label>14.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Altraif</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Lilly</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wanless</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Heathcote</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Cholestatic liver disease with ductopenia (vanishing bile duct syndrome)
            after administration of clindamycin and trimethoprim-sulfamethoxazole</article-title>
          <source>Am J Gastroenterol</source>
          <year>1994</year>
          <volume>89</volume>
          <fpage>1230</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">8053440</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b15-14-le-0032">
        <label>15.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yao</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Behling</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Saab</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lyche</surname>
              <given-names>KD</given-names>
            </name>
          </person-group>
          <article-title>Trimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome</article-title>
          <source>Am J Gastroenterol</source>
          <year>1997</year>
          <volume>92</volume>
          <fpage>67</fpage>
          <lpage>9</lpage>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f1-14-le-0032" position="float">
      <label>Figure 1 -</label>
      <caption>
        <p>Severe cholestasis with bile inside the hepatocytes and numerous bile casts in the
          canaliculi, predominantly in the pericentrilobular zone; small numbers of mononuclear
          cells and neutrophils infiltrate into the vicinity of the cholestasis (HE, &#xD7;
          400)</p>
      </caption>
      <graphic xlink:href="14-le-0032f1"/>
    </fig>
    <fig id="f2-14-le-0032" position="float">
      <label>Figure 2 -</label>
      <caption>
        <p>Evolution of alkaline phosphatase, gamma glutamyl transpeptidase (GGT), and total
          bilirubin; UNL: upper normal limit</p>
      </caption>
      <graphic xlink:href="14-le-0032f2"/>
    </fig>
    <table-wrap id="t1-14-le-0032" position="float">
      <label>Table 1 -</label>
      <caption>
        <p>Cases of Trimethoprim-sulfamethoxazole (TMT-SMX) induced cholestasis</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" rowspan="1" colspan="1">Publication</th>
            <th align="center" rowspan="1" colspan="1">Age</th>
            <th align="center" rowspan="1" colspan="1">Sex</th>
            <th align="center" rowspan="1" colspan="1">Time interval between the use of TMT-SMX and
              the beginning of the symptoms</th>
            <th align="center" rowspan="1" colspan="1">Total bilirubin (mg/dL)</th>
            <th align="center" rowspan="1" colspan="1">Time interval between the interruption of
              TMT-SMX and normalization of bilirubin</th>
            <th align="center" rowspan="1" colspan="1">Rechallenge</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="1" colspan="1">Ogilvie et al., 1980 (<xref ref-type="bibr" rid="b8-14-le-0032">8</xref>)</td>
            <td align="center" rowspan="1" colspan="1">70</td>
            <td align="center" rowspan="1" colspan="1">F</td>
            <td align="center" rowspan="1" colspan="1">Just after a 7-day course</td>
            <td align="center" rowspan="1" colspan="1">22.3</td>
            <td align="center" rowspan="1" colspan="1">6 months</td>
            <td align="center" rowspan="1" colspan="1">Yes, inadvertently, positive</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Nair et al., 1980 (<xref ref-type="bibr" rid="b9-14-le-0032">9</xref>)</td>
            <td align="center" rowspan="1" colspan="1">61</td>
            <td align="center" rowspan="1" colspan="1">M</td>
            <td align="center" rowspan="1" colspan="1">After 1 month on therapy</td>
            <td align="center" rowspan="1" colspan="1">8.8</td>
            <td align="center" rowspan="1" colspan="1">1 month</td>
            <td align="center" rowspan="1" colspan="1">No</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Steinbrecher and Mishkin, 1981 (<xref ref-type="bibr" rid="b10-14-le-0032">10</xref>)</td>
            <td align="center" rowspan="1" colspan="1">53</td>
            <td align="center" rowspan="1" colspan="1">F</td>
            <td align="center" rowspan="1" colspan="1">Just after a 10-day course</td>
            <td align="center" rowspan="1" colspan="1">9</td>
            <td align="center" rowspan="1" colspan="1">1 month</td>
            <td align="center" rowspan="1" colspan="1">Yes, inadvertently and after informed
              consent, both positive</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Coto et al., 1981 (<xref ref-type="bibr" rid="b11-14-le-0032">11</xref>)</td>
            <td align="center" rowspan="1" colspan="1">55</td>
            <td align="center" rowspan="1" colspan="1">M</td>
            <td align="center" rowspan="1" colspan="1">In the 3rd week of therapy</td>
            <td align="center" rowspan="1" colspan="1">7.1</td>
            <td align="center" rowspan="1" colspan="1">1.5 month</td>
            <td align="center" rowspan="1" colspan="1">No</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Abi-Mansur et al., 1981 (<xref ref-type="bibr" rid="b5-14-le-0032">5</xref>)</td>
            <td align="center" rowspan="1" colspan="1">52</td>
            <td align="center" rowspan="1" colspan="1">F</td>
            <td align="center" rowspan="1" colspan="1">In the 7th day of therapy</td>
            <td align="center" rowspan="1" colspan="1">11.2</td>
            <td align="center" rowspan="1" colspan="1">3 months</td>
            <td align="center" rowspan="1" colspan="1">No</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Mu&#xF1;oz et al., 1990 (<xref ref-type="bibr" rid="b7-14-le-0032">7</xref>)</td>
            <td align="center" rowspan="1" colspan="1">60</td>
            <td align="center" rowspan="1" colspan="1">F</td>
            <td align="center" rowspan="1" colspan="1">In the 4th day of therapy</td>
            <td align="center" rowspan="1" colspan="1">37</td>
            <td align="center" rowspan="1" colspan="1">8 months</td>
            <td align="center" rowspan="1" colspan="1">No</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Kowdley et al., 1992 (<xref ref-type="bibr" rid="b6-14-le-0032">6</xref>)</td>
            <td align="center" rowspan="1" colspan="1">48</td>
            <td align="center" rowspan="1" colspan="1">F</td>
            <td align="center" rowspan="1" colspan="1">In the 10th day of therapy</td>
            <td align="center" rowspan="1" colspan="1">34.8</td>
            <td align="center" rowspan="1" colspan="1">11 months</td>
            <td align="center" rowspan="1" colspan="1">No</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Kowdley et al., 1992 (<xref ref-type="bibr" rid="b6-14-le-0032">6</xref>)</td>
            <td align="center" rowspan="1" colspan="1">43</td>
            <td align="center" rowspan="1" colspan="1">F</td>
            <td align="center" rowspan="1" colspan="1">In the 7th day of therapy</td>
            <td align="center" rowspan="1" colspan="1">36.8</td>
            <td align="center" rowspan="1" colspan="1">12 months</td>
            <td align="center" rowspan="1" colspan="1">No</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Altraif et al., 1994 (<xref ref-type="bibr" rid="b14-14-le-0032">14</xref>)</td>
            <td align="center" rowspan="1" colspan="1">30</td>
            <td align="center" rowspan="1" colspan="1">M</td>
            <td align="center" rowspan="1" colspan="1">In the 4th day of therapy</td>
            <td align="center" rowspan="1" colspan="1">2.5</td>
            <td align="center" rowspan="1" colspan="1">Few weeks, but pruritus persisted for longer
              than one year</td>
            <td align="center" rowspan="1" colspan="1">No</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Ruiz-Irastorza et al., 1996 (<xref ref-type="bibr" rid="b13-14-le-0032">13</xref>)</td>
            <td align="center" rowspan="1" colspan="1">38</td>
            <td align="center" rowspan="1" colspan="1">F</td>
            <td align="center" rowspan="1" colspan="1">1 day after a single dose</td>
            <td align="center" rowspan="1" colspan="1">10.7</td>
            <td align="center" rowspan="1" colspan="1">5 months: total bilirubin 1.5 One year: total
              bilirubin normal</td>
            <td align="center" rowspan="1" colspan="1">No</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Yao et al., 1997 (<xref ref-type="bibr" rid="b15-14-le-0032">15</xref>)</td>
            <td align="center" rowspan="1" colspan="1">57</td>
            <td align="center" rowspan="1" colspan="1">M</td>
            <td align="center" rowspan="1" colspan="1">In the 5th day of therapy</td>
            <td align="center" rowspan="1" colspan="1">40.4</td>
            <td align="center" rowspan="1" colspan="1">It did not normalize. Because of clinical
              deterioration, the patient underwent ortthotopic liver transplantation 9 months after
              the beginning of symptoms</td>
            <td align="center" rowspan="1" colspan="1">No</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Kouklakis et al., 2007 (<xref ref-type="bibr" rid="b4-14-le-0032">4</xref>)</td>
            <td align="center" rowspan="1" colspan="1">30</td>
            <td align="center" rowspan="1" colspan="1">M</td>
            <td align="center" rowspan="1" colspan="1">11 days after a 15-day course</td>
            <td align="center" rowspan="1" colspan="1">6.9</td>
            <td align="center" rowspan="1" colspan="1">40 days</td>
            <td align="center" rowspan="1" colspan="1">No</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn1-14-le-0032">
          <p>F: female; M: male</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
